Skip to content
OpenCapital
Get started

Inovio Pharmaceuticals INO Q4 2024 Annual earnings

Reported March 18, 2025 · After market close

Revenue$117.0KBeat by $67.0KDiluted EPS-$0.69Beat by $0.18
Revenue estimate$50.0K
EPS estimate-$0.87

Next report

Aug 12, 2026 (in a month)
Revenue estimate$533.3K
EPS estimate-$0.28

Versus estimates

Revenue

Q1 2025$65.3KBeat by $55.3K
Q4 2024$117.0KBeat by $67.0K

Diluted EPS

Q1 2026-$0.28Beat by $0.02Q4 2025$0.31Beat by $0.68Q3 2025-$0.44Beat by $0.07Q2 2025-$0.61Beat by $0.02Q1 2025-$0.51Beat by $0.23
Q4 2024-$0.69Beat by $0.18

Ask the moment Inovio Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inovio Pharmaceuticals report Q4 2024 earnings?
Inovio Pharmaceuticals (INO) reported Q4 2024 earnings on March 18, 2025 after market close.
What were Inovio Pharmaceuticals's Q4 2024 revenue and EPS?
Inovio Pharmaceuticals reported revenue of $117.0K and diluted EPS of $-0.69 for Q4 2024.
Did Inovio Pharmaceuticals beat estimates in Q4 2024?
Revenue beat the consensus estimate of $50.0K by $67.0K. EPS beat the consensus estimate of $-0.87 by $0.18.
Where can I find Inovio Pharmaceuticals's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001055726-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.